Document Detail


Impact of fetal growth restriction on body composition and hormonal status at birth in infants of small and appropriate weight for gestational age.
MedLine Citation:
PMID:  17984240     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Fetal growth restriction (FGR) has been related to several health risks, which have been generally identified in small-for-gestational age (SGA) individuals.
OBJECTIVE: To evaluate the impact of FGR on body composition and hormonal status in infants born either small- or appropriate-for-gestational age (AGA).
METHODS: Fetal growth was assessed by ultrasound every 4 weeks from mid-gestation to birth in 248 high-risk pregnancies for SGA. Fetal growth velocity was calculated as change in the estimated fetal weight percentiles and FGR defined as its reduction by more than 20 percentiles from 22 gestational weeks to birth. Impact of FGR on body composition, cord insulin, IGF-I, IGF binding protein-3 (IGFBP-3), and cortisol concentrations was assessed in SGA and AGA newborns.
RESULTS: Growth-retarded AGA infants showed significantly reduced birth weight, ponderal index, percentage of fat mass, and bone mineral density when compared with AGA newborns with stable intrauterine growth. Cord IGF-I and IGFBP-3 concentrations were significantly decreased in growth-retarded infants in both SGA and AGA groups. Cord insulin concentration was significantly lower and cord cortisol significantly higher in AGA infants with FGR versus AGA newborns with stable intrauterine growth. After adjustment for gestational age and gender, birth weight was directly related to fetal growth velocity and cord IGF-I concentration. The variation in infant's adiposity was best explained by fetal growth velocity and cord insulin concentration.
CONCLUSIONS: FGR affects body composition and hormonal parameters in newborns with birth weight within the normal range, suggesting these individuals could be at similar metabolic risks as SGA. .
Authors:
R Verkauskiene; J Beltrand; O Claris; D Chevenne; S Deghmoun; S Dorgeret; M Alison; P Gaucherand; O Sibony; C Lévy-Marchal
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  157     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-11-06     Completed Date:  2007-12-06     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  605-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Birth Weight / physiology*
Body Composition / physiology*
Female
Fetal Development / physiology
Fetal Growth Retardation / blood*,  physiopathology
Gestational Age
Hormones / blood*
Humans
Hydrocortisone / blood
Infant, Newborn
Infant, Small for Gestational Age / blood*,  growth & development
Insulin / blood
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor Binding Proteins / blood
Male
Pregnancy
Chemical
Reg. No./Substance:
0/Hormones; 0/IGFBP3 protein, human; 0/Insulin; 0/Insulin-Like Growth Factor Binding Protein 3; 0/Insulin-Like Growth Factor Binding Proteins; WI4X0X7BPJ/Hydrocortisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measure...
Next Document:  Acute exercise increases adipose tissue interstitial adiponectin concentration in healthy overweight...